Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Purchased by Blair William & Co. IL

Blair William & Co. IL increased its stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) by 32.2% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 227,630 shares of the company’s stock after purchasing an additional 55,450 shares during the period. Blair William & Co. IL’s holdings in Cardiff Oncology were worth $505,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Ground Swell Capital LLC acquired a new stake in shares of Cardiff Oncology during the second quarter worth $38,000. Dimensional Fund Advisors LP lifted its position in Cardiff Oncology by 34.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 19,098 shares of the company’s stock worth $42,000 after acquiring an additional 4,892 shares during the period. American Century Companies Inc. grew its stake in Cardiff Oncology by 98.7% during the 2nd quarter. American Century Companies Inc. now owns 45,360 shares of the company’s stock valued at $101,000 after purchasing an additional 22,536 shares during the last quarter. Rhumbline Advisers acquired a new position in shares of Cardiff Oncology in the second quarter valued at about $102,000. Finally, Thoroughbred Financial Services LLC purchased a new position in shares of Cardiff Oncology in the second quarter worth about $116,000. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Cardiff Oncology Stock Performance

NASDAQ:CRDF opened at $2.68 on Thursday. The firm’s fifty day moving average is $2.35 and its two-hundred day moving average is $3.28. The firm has a market cap of $124.75 million, a price-to-earnings ratio of -3.07 and a beta of 1.95. Cardiff Oncology, Inc. has a one year low of $0.94 and a one year high of $6.42.

Cardiff Oncology (NASDAQ:CRDF) last posted its earnings results on Thursday, August 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.01). The company had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.12 million. Cardiff Oncology had a negative return on equity of 62.65% and a negative net margin of 6,143.91%. During the same period last year, the business earned ($0.25) earnings per share. As a group, equities research analysts predict that Cardiff Oncology, Inc. will post -1 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Craig Hallum initiated coverage on Cardiff Oncology in a research report on Friday, September 6th. They issued a “buy” rating and a $8.00 target price on the stock.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.